Loading…
Loading…
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $472.57, marking a -1.96% move from the previous day.
ABN Amro Investment Solutions boosted its position in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 257.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,216 shares of the pharmaceutical company's stock after buying an additional 49,146 shares during the quarter.
Andra AP fonden cut its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 33.5% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,903 shares of the pharmaceutical company's stock after selling 12,037 shares during the quarter. Andra
Amova Asset Management Americas Inc. lowered its stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 66.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,115 shares of the pharmaceutical company's stock after selling 4,199 shares during the period. Amova
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $480.5, denoting a -1.06% move from the preceding trading day.
Boston Common Asset Management LLC grew its position in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 7.0% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 17,205 shares of the pharmaceutical company's stock after purchasing an additional 1,124 shares
Broderick Brian C grew its position in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 8.5% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 18,656 shares of the pharmaceutical company's stock after buying an additional 1,454 shares during the period. Vertex Pharmaceuticals makes up about 1.5% of
Vertex Pharmaceuticals' latest acquisition grants it access to products with $5 billion peak annual sales potential. The company's business is strong thanks to its dominance in its core market and new launches in other areas.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for VRTX and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.